Please assess the completion status of the following clinical trial:

Trial Title: Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Aged 4 weeks or younger (0-28 days)~* \>36 weeks gestational age at birth~* Birth weight ≥2500 g~* Plasma ammonia level at presentation \>150 mcmol/L~* PA or MMA presumed or established diagnosis as follows (one of the following):~  1. Acidosis at presentation, pH \<7.3 OR~ 2. Plasma acylcarnitine analysis either alone or as part of newborn screening, demonstrating C3 \>4 mcmol/L OR~ 3. Diagnosed, or sibling diagnosed with PA by semi-quantitative urine organic acid analysis, defined as presence of elevated methylcitric acid and no evidence of biotin related disorders in the organic acid analysis OR~ 4. Diagnosed, or sibling diagnosed with MMA by semi-quantitative urine organic acid analysis, defined as elevation of methylmalonic acid and no evidence of vitamin B12 dependent disorder on plasma amino acid analysis~* Able to receive medications orally, by nasogastric (NG)-tube or by gastric (G)-tube~* No concomitant illness which would preclude safe participation as judged by the investigator~* Signed informed consent by the subject's legally acceptable representative~* After initial enrollment, criteria 3 or 4 (definitive diagnosis of the patient) must be fulfilled prior to discharge from initial admission in order to remain in the study.~Exclusion Criteria~* Had any prior hyperammonemic episode~* Administration of NCG within 7 days of participation in the study~* Use of any other investigational drug, biologic, or therapy, with the exception of sodium benzoate or sodium phenylacetate if the latter were administered prior to diagnosis by acylcarnitine analysis (diagnostic inclusion criterion 2), or organic acid analysis (diagnostic inclusion criteria 3 \& 4)~* Planned participation in any other clinical trial~* Diagnosis of any medical condition causing hyperammonemia which is not PA or MMA.~* Any clinical or laboratory abnormality or medical condition that, at the discretion of the investigator, may put the subject at an additional risk by participating in this study~* Had a liver transplant or is scheduled for a liver transplant~* Is not expected to be compliant with this study in terms of returning to site for subsequent episodes of hyperammonemia crises or for long-term follow-up

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 4 Weeks
- Healthy Volunteers: f

Study Arms:
- N-Carbamylglutamate (Type: EXPERIMENTAL): Active NCG \& Standard of Care
- Placebo (Type: PLACEBO_COMPARATOR): Standard of Care therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).